# Trial Testing Safety of IL-21 NK Cells for Induction of R/R AML

> **NCT04220684** · PHASE1 · COMPLETED · sponsor: **Sumithira Vasu** · enrollment: 19 (actual)

## Conditions studied

- Allogeneic Stem Cell Transplant Recipient
- Blasts 10 Percent or More of Bone Marrow Nucleated Cells
- Recurrent Acute Myeloid Leukemia
- Refractory Acute Myeloid Leukemia

## Interventions

- **DRUG:** Cytarabine Hydrochloride
- **DRUG:** Fludarabine
- **BIOLOGICAL:** Membrane-bound Interleukin-21-Expanded Haploidentical Natural Killer Cells

## Key facts

- **NCT ID:** NCT04220684
- **Lead sponsor:** Sumithira Vasu
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-06-11
- **Primary completion:** 2024-10-22
- **Final completion:** 2024-10-22
- **Target enrollment:** 19 (ACTUAL)
- **Last updated:** 2026-01-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04220684

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04220684, "Trial Testing Safety of IL-21 NK Cells for Induction of R/R AML". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT04220684. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*